Amgen Inc. (NASDAQ:AMGN) Shares Sold by Kintegral Advisory LLC

Kintegral Advisory LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 4.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 31,935 shares of the medical research company’s stock after selling 1,488 shares during the quarter. Amgen comprises approximately 0.8% of Kintegral Advisory LLC’s investment portfolio, making the stock its 24th biggest holding. Kintegral Advisory LLC’s holdings in Amgen were worth $8,324,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the third quarter worth about $25,000. Centricity Wealth Management LLC bought a new stake in Amgen in the fourth quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the third quarter worth approximately $29,000. Heck Capital Advisors LLC bought a new stake in shares of Amgen during the fourth quarter worth $36,000. Finally, PrairieView Partners LLC raised its position in shares of Amgen by 118.3% during the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 97 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Amgen stock opened at $303.01 on Friday. The company has a market cap of $162.78 billion, a PE ratio of 40.13, a price-to-earnings-growth ratio of 2.55 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company’s 50-day moving average price is $276.27 and its 200-day moving average price is $300.59. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts forecast that Amgen Inc. will post 20.6 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.14%. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is presently 126.09%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AMGN. Bank of America lifted their price target on shares of Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a research report on Thursday, February 6th. Piper Sandler increased their price target on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Royal Bank of Canada restated an “outperform” rating and set a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Leerink Partners reduced their target price on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $314.09.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the transaction, the executive vice president now directly owns 44,186 shares of the company’s stock, valued at $13,025,590.94. The trade was a 16.56 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.